Results 201 to 210 of about 140,006 (312)

Heat shock protein 72 (HSP72) modulates glucagon secretion via JNK inhibition in pancreatic α-cells. [PDF]

Diabetol Int
Watanabe T, Kondo T, Yoshizumi R, Miyakawa N, Kitano S, Suico MA, Sato M, Sakaguchi M, Igata M, Matsumura T, Kai H, Araki E, Kubota N.   +12 more
europepmc   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025

Obesity, EarlyView.
ABSTRACT Objective Use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) has increased rapidly following approval for obesity treatment, but data on their use in younger populations remain limited. We examined trends in GLP‐1RA use among 12– to 24‐year‐olds in Denmark during 2018–2025.
Helene Kildegaard, Jacob Harbo Andersen, Rebecca Kofod Vinding, Julie Tonsgaard Kloppenborg, Anton Pottegård   +4 more
wiley   +1 more source

Heterogeneous endocrine cell composition defines human islet functional phenotypes. [PDF]

Nat Commun
Evans-Molina C, Pettway YD, Saunders DC, Sharp SA, Bate TS, Sun H, Durai H, Mei S, Coldren A, Davis C, Reihsmann CV, Hopkirk AL, Taylor J, Bradley A, Aramandla R, Poffenberger G, Eskaros A, Jenkins R, Shi D, Xu K, Kang H, Rajesh V, Thaman S, Feng F, Cartailler JP, Powers AC, Abraham K, IIDP Consortium, Gloyn AL, Niland JC, Brissova M.   +30 more
europepmc   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Glucose-dependent dynamics of glucagon, cortisol and adrenocorticotropic hormone before and after gastric bypass. [PDF]

J Endocr Soc
Chronopoulos V, Kjellsson MC, Lundqvist MH.   +2 more
europepmc   +1 more source

Appetite Suppression by GLP‐1 Receptor Agonists: Role of Delayed Gastric Emptying

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate relationships between delayed gastric emptying and appetite suppression during treatment with liraglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA). Methods We conducted a secondary data analysis from a 16‐week randomized, placebo‐controlled liraglutide trial in patients with obesity.
Mark I. Friedman, W. Scott Harmsen, Michael Camilleri   +2 more
wiley   +1 more source

Effects of Intermittent Fasting-Mimicking Diet on Pancreatic Islet Plasticity: Immunohistochemical, Ultrastructural, and Metabolic Profiles. [PDF]

FASEB J
Harer CM, Boulgaropoulos B, Ehall B, Bogensperger L, Bounab K, Pernitsch D, Franz J, Herbsthofer L, Kotzbeck P, Krstic J, Prokesch A, Prietl B, Kolb D, Pieber TR.   +13 more
europepmc   +1 more source

Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence

Obesity, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies.
Janice Bidesie, Erik Oudman
wiley   +1 more source

Paracrine inhibition via G protein inwardly rectifying potassium channels regulates glucagon secretion from human pancreatic alpha cells. [PDF]

Cell Rep
Panzer JK, Lang AL, Levi NJ, Garcia PA, Barro-Soria R, Caicedo A.   +5 more
europepmc   +1 more source